Metabolic and Hormonal Effects of Oral DHEA in Premenopausal Women with HIV Infection: A Randomized, Prospective, Placebo-controlled Pilot Study

Abstract

Women with HIV infection use dehydroepiandrosterone (DHEA) because of its potential effects on mood and energy. We examined the effects of DHEA on the hypothalamic–pituitary–adrenal and gonadal axes and on insulin sensitivity. Fifteen HIV-positive women were randomized to receive placebo (6 subjects) or oral DHEA (9 subjects). ACTH-, CRF-, and GnRH-stimulation tests were performed before and after 8 weeks of treatment. DHEA, DHEA-S, dihydrotestosterone, total testosterone, free testosterone, sex hormone–binding globulin, estrone, estradiol, cortisol, insulin, IGF-1, IGFBP-1, IGFBP-3, and adiponectin in plasma or serum were measured. There was a significant increase in DHEA (p<0.004), DHEA-S (p<0.008), total testosterone (p<0.008), dihydrotestosterone (p<0.004), androstenedione (p<0.04), and estrone (p<0.03) from baseline within the DHEA group but not within the placebo group. There was a significant increase in DHEA (p<0.0006), DHEA-S (p<0.032), total testosterone (p<0.01), and dihydrotestosterone (p<0.005) in the DHEA group compared with the placebo group. Oral DHEA produces significant increases in circulating DHEA, DHEA-S, testosterone, DHT, and, possibly, androstenedione and estrone levels in premenopausal women with HIV infection. In the current pilot study these hormone changes did not affect the pituitary or adrenal axis or insulin/IGF indices. Long-term studies with larger groups of patients are needed to confirm these data and to determine their clinical significance.

Key words

endocrine effects - DHEA - HIV infection - premenopausal women - insulin sensitivity

References

• 1 Quinn TC, Overbaugh J. 2005 HIV/AIDS in women: an expanding epidemic.  Science. 2005;  308 1582-1583
• 2 NCHS-CDC . National vital statistics report. 2003;  52 ((9))
• 3 Rabkin JG, MacElhiney M, Rabkin R, MacGrath P, Ferrando S. DHEA effects on mild depression in HIV/AIDS: A placebo-controlled trial.  Am J Psychiatry. 2006;  163 59-66
• 4 Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentration throughout adulthood.  J Clin Endocrinol Metab. 1984;  59 551-555
• 5 Jacobson MA, Fusaro R, Galmarini M, Lang W. Decreased serum dehydroepiandrosterone is associated with an increased progression of HIV infection in men with CD4 cell counts 200–499.  J Infect Disease. 1991;  164 864-868
• 6 Barrett-Connor E, Muhlen D von, Laughlin G, Kripke A. Endogenous levels of DHEA sulfate, but not other sex hormones, are associated with depressed mood in older women: The Rancho Bernardo Study.  J Am Geriatr Soc. 1999;  47 685-691
• 7 Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+patients: effects on mood, androgenic and anabolic parameters.  Psychoneuroendocrinology. 2000;  25 53-68
• 8 Villareal DT, Hollorzy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men.  JAMA. 2004;  292 2243-2248
• 9 Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men.  J Clin Endocrinol Metab. 1988;  66 57-61
• 10 Kudielka BM, Hellhammer J, Hellhammer DH. Sex differences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of two week dehydroepiandrosterone treatment.  J Clin Endocrinol Metab. 1998;  83 1756-1761
• 11 Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six month treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.  Clin Endocrin (Oxf). 1998;  49 421-432
• 12 Christeff N, Gharakhanian S, Thobie N, Rozenbaum W, Nunez EA. Evidence for changes in adrenal and testicular steroids during HIV infection.  Psychoneuroendocrinology. 1997;  22 ((Suppl 1)) S11-S18
• 13 Torre B De la, Krogh G von, Svensson M, Holmberg V. Blood cortisol and dehydroepiandrosterone sulphate (DHEAS) levels and CD4 T cell counts in HIV infection.  Clin Exp Rheumatol. 1997;  15 87-90
• 14 Ferrando JF, Rabkin JG, Poretsky L. Dehydroepiandrosterone sulfate (DHEAS) and testosterone: relation to HIV disease illness stage and progression over one year.  J Acquir Immune Defic Syndr. 1999;  22 146-154
• 15 Arlt W, Cllies F, Vlijmen JC van, Koehler L, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency.  N Engl J Med. 1999;  341 1013-1020
• 16 Poretsky L, Brillon DJ, Ferrando S, Chiu J, MacElhiney M, Ferenczi A, Sison M, Haller I, Rabkin J. Endocrine effects of oral dehydroepiandrosterone in men with HIV infection: a prospective, randomized, double-blind, placebo-controlled trial.  Metabol Clin Exper. 2006;  55 858-870
• 17 Grispoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.  N Engl J Med. 2005;  352 48-62
• 18 Membreno L, Irony I, Dere W, Klein R, Biglieri EG, Cobb E. Adrenocortical function in acquired immunodeficiency syndrome.  J Clin Endocrinol Metab. 1987;  65 482-487
• 19 Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer.  N Engl J Med. 2006;  354 270-282

Correspondence